Review



lalistat2  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress lalistat2
    Lalistat2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lalistat2/product/MedChemExpress
    Average 93 stars, based on 2 article reviews
    lalistat2 - by Bioz Stars, 2026-02
    93/100 stars

    Images



    Similar Products

    lalistat2  (MedChemExpress)
    93
    MedChemExpress lalistat2
    Lalistat2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lalistat2/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    lalistat2 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    lalistat2 tocris  (Tocris)
    93
    Tocris lalistat2 tocris
    Lalistat2 Tocris, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lalistat2 tocris/product/Tocris
    Average 93 stars, based on 1 article reviews
    lalistat2 tocris - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    lalistat2 buffer  (MedChemExpress)
    93
    MedChemExpress lalistat2 buffer
    Lalistat2 Buffer, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lalistat2 buffer/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    lalistat2 buffer - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    lalistat2  (Tocris)
    90
    Tocris lalistat2
    KEY RESOURCES TABLE
    Lalistat2, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lalistat2/product/Tocris
    Average 90 stars, based on 1 article reviews
    lalistat2 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    substrate mix lalistat2  (Millipore)
    90
    Millipore substrate mix lalistat2
    KEY RESOURCES TABLE
    Substrate Mix Lalistat2, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/substrate mix lalistat2/product/Millipore
    Average 90 stars, based on 1 article reviews
    substrate mix lalistat2 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    lal inhibitor lalistat2  (Cayman Chemical)
    90
    Cayman Chemical lal inhibitor lalistat2
    Profiles of myeloid subsets in NSCLC versus healthy subjects. (A) A representative gating strategy of CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes. (B) Statistical analysis of percentages of CD11b + HLA-DR - , CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes. (C) A representative gating strategy of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells. (D) Statistical analysis of percentages of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells. (E) Human leucocytes from healthy individuals were incubated with 10 µM <t>Lalistat2</t> (L) or DMSO (S) for 24 hours. The percentages of CD11b + HLA-DR - , CD11b + CD13 + HLA-DR - , CD11b + CD14 + HLA-DR - , and CD11b + CD15 + HLA-DR - cells were analyzed by flow cytometry. C is the control without treatment. Data are expressed as mean±SD; experiments are independently repeated, n=19–20 for (B) and (D), n=6–7 for (E). *p<0.05, **p<0.01. NSCLC, non-small cell lung cancer.
    Lal Inhibitor Lalistat2, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lal inhibitor lalistat2/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    lal inhibitor lalistat2 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    lalistat2  (Millipore)
    90
    Millipore lalistat2
    Profiles of myeloid subsets in NSCLC versus healthy subjects. (A) A representative gating strategy of CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes. (B) Statistical analysis of percentages of CD11b + HLA-DR - , CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes. (C) A representative gating strategy of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells. (D) Statistical analysis of percentages of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells. (E) Human leucocytes from healthy individuals were incubated with 10 µM <t>Lalistat2</t> (L) or DMSO (S) for 24 hours. The percentages of CD11b + HLA-DR - , CD11b + CD13 + HLA-DR - , CD11b + CD14 + HLA-DR - , and CD11b + CD15 + HLA-DR - cells were analyzed by flow cytometry. C is the control without treatment. Data are expressed as mean±SD; experiments are independently repeated, n=19–20 for (B) and (D), n=6–7 for (E). *p<0.05, **p<0.01. NSCLC, non-small cell lung cancer.
    Lalistat2, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lalistat2/product/Millipore
    Average 90 stars, based on 1 article reviews
    lalistat2 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    KEY RESOURCES TABLE

    Journal: Cell reports

    Article Title: Pro-survival signaling regulates lipophagy essential for multiple myeloma resistance to stress-induced death

    doi: 10.1016/j.celrep.2024.114445

    Figure Lengend Snippet: KEY RESOURCES TABLE

    Article Snippet: Lalistat2 , Tocris , Cat#6099.

    Techniques: Ubiquitin Proteomics, Recombinant, Staining, SYBR Green Assay, cDNA Synthesis, Clinical Proteomics, Cell Isolation, Isolation, Control, shRNA, Plasmid Preparation, Software

    Profiles of myeloid subsets in NSCLC versus healthy subjects. (A) A representative gating strategy of CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes. (B) Statistical analysis of percentages of CD11b + HLA-DR - , CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes. (C) A representative gating strategy of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells. (D) Statistical analysis of percentages of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells. (E) Human leucocytes from healthy individuals were incubated with 10 µM Lalistat2 (L) or DMSO (S) for 24 hours. The percentages of CD11b + HLA-DR - , CD11b + CD13 + HLA-DR - , CD11b + CD14 + HLA-DR - , and CD11b + CD15 + HLA-DR - cells were analyzed by flow cytometry. C is the control without treatment. Data are expressed as mean±SD; experiments are independently repeated, n=19–20 for (B) and (D), n=6–7 for (E). *p<0.05, **p<0.01. NSCLC, non-small cell lung cancer.

    Journal: Journal for Immunotherapy of Cancer

    Article Title: LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer

    doi: 10.1136/jitc-2022-006272

    Figure Lengend Snippet: Profiles of myeloid subsets in NSCLC versus healthy subjects. (A) A representative gating strategy of CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes. (B) Statistical analysis of percentages of CD11b + HLA-DR - , CD13 + , CD14 + , CD15 + , and CD33 + cells in the leucocytes. (C) A representative gating strategy of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells. (D) Statistical analysis of percentages of CD13 + , CD14 + , CD15 + , and CD33 + cells in CD11b + HLA-DR - cells. (E) Human leucocytes from healthy individuals were incubated with 10 µM Lalistat2 (L) or DMSO (S) for 24 hours. The percentages of CD11b + HLA-DR - , CD11b + CD13 + HLA-DR - , CD11b + CD14 + HLA-DR - , and CD11b + CD15 + HLA-DR - cells were analyzed by flow cytometry. C is the control without treatment. Data are expressed as mean±SD; experiments are independently repeated, n=19–20 for (B) and (D), n=6–7 for (E). *p<0.05, **p<0.01. NSCLC, non-small cell lung cancer.

    Article Snippet: To inhibit LAL activity, human blood cells from healthy participants had the red cells removed with lysis buffer (BioLegend, San Diego, California, USA), washed with phosphate-buffered saline (PBS) by centrifugation at 240× g for 5 min at room temperature, and then incubated with 10 μM LAL inhibitor Lalistat2 (Cayman, Ann Arbor, Michigan, USA) for 24 hours.

    Techniques: Incubation, Flow Cytometry, Control